Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2023-08-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房第四届监事会第二十五次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of Yifeng Pharmacy Chain Co., Ltd. It details the resolution passed in the 25th meeting of the 4th supervisory board, specifically about extending the validity period of a convertible bond issuance plan. The document includes voting results and confirms compliance with relevant laws and company articles. It is not a full financial report, audit report, or earnings release. It is an official announcement of a board resolution related to financing activities (extension of convertible bond issuance plan). Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (900 characters), but it contains substantive content about a financing decision, not just a notice of report publication or certification. Hence, CAP is appropriate with high confidence.
2023-08-27 Chinese
益丰药房关于召开2023年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 third extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes an authorization letter template for proxy voting. There is no financial data, earnings, or report content. The document is an announcement of a shareholder meeting, not a report or results announcement. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the voting results or solicitation materials, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and is a meeting notice with voting agenda and proxy form, typical of PSI filings.
2023-08-27 Chinese
独立董事关于公司第四届董事会第三十次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion regarding the extension of the validity period for a convertible bond issuance plan and related authorization. It references compliance with company law, securities law, and internal company rules. The content focuses on governance and approval procedures related to a capital financing activity (issuance of convertible bonds). It is not a full financial report, audit, or earnings release, but rather a governance-related statement tied to a capital market transaction. Given the focus on issuance of convertible bonds and authorization extension, the document best fits the category of Capital/Financing Update (CAP). The document length is short and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2023-08-27 Chinese
益丰药房关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Yifeng Pharmacy Chain Co., Ltd. regarding the completion of industrial and commercial registration changes. It details the updated company registration information such as company name, type, address, legal representative, registered capital, establishment date, business scope, and other administrative details. There is no financial data, no mention of financial results, no discussion of management changes, no voting results, no legal proceedings, and no mention of any report being attached or published. The document is a regulatory announcement about company registration information changes, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category.
2023-08-18 Chinese
独立董事关于公司第四届董事会第二十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting item about the repurchase and cancellation of restricted stock under the 2022 restricted stock incentive plan. It references compliance with regulatory rules and company bylaws, and provides an independent opinion on the matter. The document is short (560 characters) and focuses on a specific board-related matter rather than a full report or announcement of financial results. It is not a full audit report, annual report, or earnings release. It is not a general regulatory filing or a report publication announcement. The content aligns best with Board/Management Information (MANG) as it relates to board decisions and management actions regarding stock repurchase and cancellation under an incentive plan.
2023-08-14 Chinese
益丰药房关于第二次回购注销2022年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from a company regarding the repurchase and cancellation of restricted shares under a 2022 restricted stock incentive plan. It details the number of shares repurchased, the price, the legal and board approvals, and the impact on share capital structure. The document is a formal disclosure about a share repurchase related to an employee stock incentive plan, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction itself. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2023-08-14 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.